OTI-010 Osiris Therapeutics/JCR Pharmaceuticals.
Osiris Therapeutics is developing the donor-derived mesenchymal stem cell (MSC) therapy OTI-010, which repopulates the bone marrow stroma and thus supports engraftment of hematopoietic stem cells from the same donor. This stem cell therapy, which has been awarded Orphan Drug status, is currently in development for the potential enhancement of bone marrow transplants in cancer patients, for the prevention of graft versus host disease (GVHD), and for the treatment of Crohn's disease. Japanese licensee JCR Pharmaceuticals is investigating the therapy for the potential treatment of GVHD in patients undergoing bone marrow transplantation to treat leukemia. Phase II clinical trials in acute gastrointestinal GVHD and in adult and pediatric patients with treatment-refractory severe GVHD are currently underway.
Taupin
Philippe
P
National Neuroscience Institute, National University of Singapore, Singapore. obgpjt@nus.edu.sg
D000293:Adolescent; D000328:Adult; D000818:Animals; D016026:Bone Marrow Transplantation / Q000379:methods*; D018929:Cell Culture Techniques; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000628:therapy; D006086:Graft vs Host Disease / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods; D008875:Middle Aged; D009965:Orphan Drug Production; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous